A recent study published by researchers out of the Rizzoli Orthopedic Institute in Bologna, Italy compared the effects of various PRP formulations on human chondrocytes in Vitro. Primary researchers include Dr. Elisaveta Kon, who is scheduled to lecture on “PRP for Cartilage Pathology” at the 2014 TOBI: The Orthobiologic Institute Regenerative Medicine Symposium in Las Vegas.
The study compared PRP derived from blood samples of 10 patients, which was prepared in 3 different formulations:
1. (P-PRP) PRP with a relatively low concentration of platelets and very few leukocytes
2. (L-PRP) PRP with high concentrations of both platelets and leukocytes
3. (PPP) platelet-poor plasma
Each of the three formulations was measured for specific growth factor concentrations, and exposed to chondrocytes derived from osteoarthritic cartilage. The cellular proliferation, matrix production, and gene expression of the chondrocytes was analyzed following the culture period.
The results revealed that although all of the PRP formulations increased chondrocyte proliferation, P-PRP exhibited larger cellular proliferation on Day #7 in comparison to the other two formulations, and was also shown to increase chondrocyte anabolism, expressed through Type II-collagen and Aggrecan. On the other hand, L-PRP contained the highest concentration of growth factors and cytokines, which was shown to promote more catabolic pathways. In addition, L-PRP-exposed chondrocytes exhibited greater expression of the Hyaluronic Acid Synthase-2 gene, which correlated with larger concentrations of Hyaluronan when compared to cell cultures with P-PRP.
The study concluded that although L-PRP and P-PRP both stimulated chondrocyte proliferation, the unique differences in anabolic and catabolic effects on chondrocytes could potentially be due to differences in the concentration of platelets, leukocytes, growth factors, and other bioactive molecules. Continued research and collaboration are essential to identifying the optimal ratio and cellular concentrations of these blood components. Although more in Vitro studies, as well as human trials, are needed to discover the most advantageous PRP formulation for cartilage healing, research continues to grow in this area and looks to be a continuing trend for the future.
Be sure to attend the 5th annual 2014 TOBI: The Orthobiologic Institute PRP and Regenerative Medicine Symposium June 6th and 7th in Las Vegas, for the most cutting edge research in Platelet Rich Plasma, including Dr. Elizaveta Kon’s lecture “PRP for Cartilage Pathology”. www.prpseminar.com